Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal research without human data
PubMed 32564332 · doi:10.1007/s11481-020-09925-8
What was done
Mice intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model Parkinson's disease were treated orally with the matrix metalloproteinase inhibitor 1-deoxynojirimycin (1-DNJ), ibuprofen, or a combination of both. Motor changes were evaluated with the open-field test. Dopaminergic neuronal integrity in the substantia nigra pars compacta was assessed by tyrosine hydroxylase (TH+) immunohistochemistry, microglial activation was assessed using Iba-1+ and CD68+ markers, and pro-inflammatory cytokines (TNF-α and IL-6) were measured by qPCR.
What was found
The abstract reports no numerical values, baseline values, or effect sizes. Monotherapy with either 1-DNJ or ibuprofen alone failed to reduce MPTP-induced damage. Combined treatment with 1-DNJ and ibuprofen prevented loss of mesencephalic dopaminergic neurons, decreased CD68+/Iba-1+ cells, reduced microglia/neuron interactions, lowered TNF-α and IL-6 expression, and improved open-field behavioral alterations relative to MPTP-treated control mice.
Why it matters
This paper suggests that simultaneously inhibiting matrix metalloproteinases and inflammatory pathways may yield synergistic neuroprotection in experimental parkinsonism where single-drug interventions fail.
Limits
The abstract does not report animal sample sizes, drug dosages, or exact numerical values with confidence intervals. Findings are restricted to a toxin-induced mouse model of Parkinson's disease and do not provide direct evidence of efficacy or safety in humans.
Cited by
- supports MPTP is converted into toxic MPP+ by monoamine oxidase B, and MPP+ is selectively transported into dopaminergic neurons of the substantia nigra via the dopamine transporter.